T. Cooper Woods, PhD
Assistant Professor, Department of Pharmacology
Tulane University Heart & Vascular Institute
Department of Physiology
Tulane University School of Medicine
1430 Tulane Avenue
1430 Tulane Avenue
BS Chemistry and Music – 1994
University of the South, Sewanee
PhD Biophysical Sciences – 1998
University of Alabama at Birmingham
Research in my laboratory aims to elucidate the impact of co-morbidities such as Diabetes Mellitus and Chronic Kidney Disease on the progression of cardiovascular disease. A focus of this research is toward understanding the molecular mechanisms underlying the increased intimal thickening seen in the diabetic population. These studies are currently examining the how the presence of diabetes promotes the acceleration of vascular smooth muscle cell proliferation and migration, two components of intimal thickening, through increases in specific microRNAs. Additional projects focus on the development of biomarkers for the identification of patients at high risk for cardiovascular disease and complications following angioplasty.
Paul F. Stahls III, Daniel J. Lightell, Jr., Stephanie C. Moss, Corey K. Goldman, T. Cooper Woods. Elevated serum bone morphogenetic protein 4 in patients with chronic kidney disease and coronary artery disease. J Cardiovasc Transl Res., Apr;6(2):232-8, 2013.
Daniel J. Lightell, Jr., Stephanie C. Moss, and T. Cooper Woods. Loss of Canonical Insulin Signaling Accelerates Vascular Smooth Muscle Cell Proliferation and Migration Through Changes in p27Kip1 Regulation, Endocrinology, 152: 651 – 658, 2011.
T. Cooper Woods. Regulation of cell migration by mTOR is mediated through changes in p27(Kip1) phosphorylation. Cell Cycle, 9(11): 2057-2058, 2010.
Stephanie C. Moss, Daniel Lightell, Jr., Steven O. Marx, Andrew R. Marx, and T. Cooper Woods. Rapamycin regulates endothelial cell migration through regulation of the cyclin-dependent kinase inhibitor, p27Kip1. J. Biol. Chem., 285 (16):11991-11997, 2010.
Stephanie C. Moss, Daniel Lightell, Jr., Richard Deichmann, and T. Cooper Woods. Sera from Diabetics does not Alter the Effect of mTOR Inhibition on Smooth Muscle Cell Proliferation. J. Cardiovascular Pharm., 53 (1):86-89, 2009.
Stephanie C. Moss, Michael Bates, Patrick E. Parrino, and T. Cooper Woods. Isolation of Endothelial Cells and Vascular Smooth Muscle Cells from Internal Mammary Artery Tissue. The Ochsner Journal, 7 (3):133-136, 2007.
Karine Oumouna-Benachour, Chetan P Hans, Yasuhiro Suzuki, Amarjit Naura, Rahul Datta, Souad Belmadani, T. Cooper Woods, and Hamid Boulares, PARP-1 Inhibition Reduces Atherosclerotic Plaque Size and Promotes Factors of Plaque Stability in ApoE-Deficient Mice: Effects on Macrophage Recruitment, NF-kappaB Nuclear Translocation, and Foam Cell Death. Circulation, 115 (18):2442-50, 2007.
Yung-Wei Chi, Christopher J. White, T. Cooper Woods, Corey K. Goldman, Ultrasound velocity criteria for carotid in-stent restenosis.Catheterization and Cardiovascular Interventions, 69(3),p349 – 354, 2006.
T. Cooper Woods and Dan W. Urry. Controlled Release of Phosphorothioates by Protein-based Polymers. Drug Delivery, 13(4), p. 253-259, 2006.
T. Cooper Woods, Frank Mercogliano, Bin Zhang, and Steven M. Dinh. Response of the Lung to Pulmonary Insulin Dosing in the Rat Model and Effects of Changes in Formulation. Diabetes Technology & Therapeutics, 7(3), p. 516-524, 2005.
T. Cooper Woods, Chad R. Blystone, and Elazer R. Edelman. Activation of EphB2 and its ligands promotes vascular smooth muscle proliferation. J. Biol. Chem., 277, p. 1924-1927, 2002.
Frederick G. P. Welt, T. Cooper Woods, Elazer R. Edelman. Oral heparin prevents neointimal hyperplasia after arterial injury: inhibitory potential depends on type of vascular injury. Circulation. 104(25) p. 3121-4, 2001.